Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #48 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Aarti Pharmalabs Limited (this stock) | 8,584 | 41.2 | 8.8% | 14.1% | 0.16% | 61 | 19 | 88 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 536 | 94 | 76 | ₹ |
| March 31, 2026 | 583 | 76 | 61 | ₹ |
| Dec. 31, 2025 | 432 | 58 | 48 | ₹ |
| Sept. 30, 2025 | 418 | 39 | 28 | ₹ |
| June 30, 2025 | 386 | 67 | 50 | ₹ |
| March 31, 2025 | 564 | 115 | 88 | ₹ |
| Dec. 31, 2024 | 538 | 101 | 74 | ₹ |
| Sept. 30, 2024 | 458 | 72 | 55 | ₹ |
| June 30, 2024 | 555 | 74 | 55 | ₹ |
| March 31, 2024 | 506 | 96 | 65 | ₹ |
| Dec. 31, 2023 | 449 | 74 | 53 | ₹ |
| Sept. 30, 2023 | 440 | 67 | 52 | ₹ |
| June 30, 2023 | 458 | 64 | 47 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 1,819 | 225 | 175 |
| March 31, 2025 | 2,115 | 361 | 272 |
| March 31, 2024 | 1,853 | 300 | 217 |
| March 31, 2023 | 1,945 | 261 | 193 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 262 | -431 | 171 | 409 | -147 |
| March 31, 2025 | 332 | -414 | 65 | 402 | -70 |
| March 31, 2024 | 216 | -215 | 10 | 156 | 61 |
| March 31, 2023 | 263 | -158 | -163 | 120 | 143 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 3,482 | 2,125 | 2,079 | 500 | 186 | 1,397 | 938 | 9 | 1,336 | 640 |
| March 31, 2025 | 2,906 | 1,990 | 1,945 | 293 | 104 | 1,322 | 657 | 7 | 1,104 | 588 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
